Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica
Non-Small Cell Lung Cancer – Adjuvant
Initial criteria
- age ≥ 18 years
- tumor negative for actionable biomarkers (EGFR exon 19 deletion or exon 21 L858R, ALK, RET, ROS1)
- completely resected or node positive disease
- tumor expresses PD-L1 ≥ 1%
- received previous adjuvant chemotherapy
- prescribed by or in consultation with an oncologist
Approval duration
1 year